Octreotide LAR
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Octreotide LAR
Octreotide LAR is a phase 3 stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT00128232. Target conditions include Acromegaly.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06784752 | Phase 3 | Recruiting |
| NCT01886287 | Phase 2 | Terminated |
| NCT00166725 | Phase 2 | Completed |
| NCT00128232 | Phase 3 | Completed |
| NCT00225979 | Phase 3 | Completed |
Competing Products
20 competing products in Acromegaly
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alesse | Novartis | Phase 2 | 52 |
| ONO-5788 + ONO-5788 Placebo + Octreotide | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-5788 + [14C]-ONO-5788 | Ono Pharmaceutical | Phase 1 | 33 |
| Pasireotide LAR | Novartis | Phase 3 | 77 |
| Octreotide acetate 30 mg suspension | Novartis | Phase 3 | 77 |
| Pasireotide long acting release formulation | Novartis | Pre-clinical | 23 |
| Sandostatin LAR + pegvisomant + cabergoline | Novartis | Approved | 85 |
| Octreotide acetate and cabergoline/Octrotide and Somavert | Novartis | Approved | 85 |
| Sandostatin LAR | Novartis | Approved | 85 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Sandostatin (Octreotide Acetate) | Novartis | Approved | 85 |
| Octreotide acetate | Novartis | Approved | 85 |
| octreotide FluidCrystal® injection depot | Novartis | Phase 2 | 52 |
| Octreotide LAR | Novartis | Phase 3 | 77 |
| Pasireotide | Novartis | Phase 2 | 52 |
| Pasireotide LAR 60 mg + Pegvisomant | Novartis | Approved | 85 |
| Octreotide | Novartis | Approved | 85 |
| Octreotide LAR 30 MG Injection | Novartis | Approved | 85 |
| Pasireotide LAR | Novartis | Phase 2 | 52 |
| Pasireotide (SOM230), Octreotide (Sandostatin) | Novartis | Phase 2 | 52 |